المؤلفون: Hiroshi Yoshida, Hiroaki Ozasa, Kentaro Hashimoto, Yusuke Shima, Keiichiro Suminaga, Hitomi Ajimizu, Takashi Nomizo, Hironori Yoshida, Masahiro Yoshioka, Masashi Kanai, Takehito Shukuya, Manabu Muto, Toyohiro Hirai

المصدر: Current Problems in Cancer: Case Reports, Vol 14, Iss , Pp 100286- (2024)

مصطلحات موضوعية: EGFR mutation, Next-geneneration sequencing, Non-small cell lung cancer, EGFR tyrosine kinase inhibitor, Treatment, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Among cases of non-small cell lung cancer (NSCLC) with EGFR mutations, NSCLC with deletions in EGFR exon 19 or 21 L858R account for 85 %. Frequency of NSCLC with minor mutations in EGFR is about 9 %, whilst EGFR exon 20 insertion mutation account for 6 % of the cases, determining it as a rare mutation. In this case, minor EGFR mutation and compound mutation EGFR H773L/V774M, were detected. Oncomine Dx target test (Oncomine), FoundationOne, and Amoy Dx polymerase chain reaction panel (Amoy 9-in-1 kit) were used as companion diagnostic tests. FoundationOne was the only one able to detect EGFR exon 20 H773L/V774M mutations. Drug therapy for NSCLC with compound mutations in EGFR exon 20 is not yet established. Unsuccessful treatments with EGFR-TKIs such as Erlotinib, Gefitinib, and Afatinib have been reported. There have also been reports of successful treatments with Osimertinib in combination with Bevacizumab. In the presented case, Osimertinib monotherapy was successful in treating NSCLC with EGFR exon 20 compound mutation. Osimertinib, therefore, has the potential to treat NSCLC with EGFR exon 20 H773L/V774M mutation, and can be a key drug for treating EGFR rare mutations.

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2666621924000097Test; https://doaj.org/toc/2666-6219Test

الوصول الحر: https://doaj.org/article/9c163bc24b6e4a9181dc97cc3c256896Test

المؤلفون: Haruka YAMAMOTO, Hideo KITA, Hiroko FUKATA, Takashi NOMIZO, Tsunetaka MURAYAMA, Yasukiyo NAKAMURA, 中村 保清, 北 英夫, 山本 晴香, 村山 恒峻, 深田 寛子, 野溝 岳

المصدر: 感染症学雑誌 / Kansenshogaku Zasshi. 2023, 97(3):98

المؤلفون: Hitomi Ajimizu, Hiroaki Ozasa, Susumu Sato, Tomoko Funazo, Yuichi Sakamori, Takashi Nomizo, Kiyomitsu Kuninaga, Tatsuya Ogimoto, Kazutaka Hosoya, Masatoshi Yamazoe, Takahiro Tsuji, Hironori Yoshida, Ryo Itotani, Kentaro Ueno, Young Hak Kim, Shigeo Muro, Toyohiro Hirai

المصدر: Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)

مصطلحات موضوعية: Medicine, Science

الوصف: Abstract Chronic obstructive pulmonary disease (COPD) may coexist with lung cancer, but the impact on prognosis is uncertain. Moreover, it is unclear whether pharmacological treatment for COPD improves the patient’s prognosis. We retrospectively investigated patients with advanced non-small-cell lung cancer (NSCLC) who had received chemotherapy at Kyoto University Hospital. Coexisting COPD was diagnosed by spirometry, and the association between pharmacological treatment for COPD and overall survival (OS) was assessed. Of the 550 patients who underwent chemotherapy for advanced NSCLC between 2007 and 2014, 347 patients who underwent spirometry were analyzed. Coexisting COPD was revealed in 103 patients (COPD group). The median OS was shorter in the COPD group than the non-COPD group (10.6 vs. 16.8 months). Thirty-seven patients had received COPD treatment, and they had a significantly longer median OS than those without treatment (16.7 vs. 8.2 months). Multivariate Cox regression analysis confirmed the positive prognostic impact of COPD treatment. Additional validation analysis revealed similar results in patients treated with immune checkpoint inhibitors (ICIs). Coexisting COPD had a significant association with poor prognosis in advanced NSCLC patients if they did not have pharmacological treatment for COPD. Treatment for coexisting COPD has the potential to salvage the prognosis.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-2322Test

الوصول الحر: https://doaj.org/article/f3c791af74a046499c35180097eeba07Test

المؤلفون: Hitomi Ajimizu, Hiroaki Ozasa, Susumu Sato, Tomoko Funazo, Yuichi Sakamori, Takashi Nomizo, Kiyomitsu Kuninaga, Tatsuya Ogimoto, Kazutaka Hosoya, Masatoshi Yamazoe, Takahiro Tsuji, Hironori Yoshida, Ryo Itotani, Kentaro Ueno, Young Hak Kim, Shigeo Muro, Toyohiro Hirai

المصدر: Scientific Reports, Vol 13, Iss 1, Pp 1-2 (2023)

مصطلحات موضوعية: Medicine, Science

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-2322Test

الوصول الحر: https://doaj.org/article/54a067459b054ee180ce6a077620ee5aTest

المؤلفون: Koichi Hasegawa, Ayano Toriyama, Takashi Nomizo, Hiroko Fukata, Kenichi Goto, Yasukiyo Nakamura, Tatsuo Hamada, Naoki Kanda, Hideo Kita

المصدر: Clinical Case Reports, Vol 8, Iss 12, Pp 3327-3331 (2020)

مصطلحات موضوعية: bacterial pleural infection, chronic pancreatitis, Enterobacter, pancreatic pleural effusion, pancreaticopleural fistula, Medicine, Medicine (General), R5-920

الوصف: Abstract Pleural empyema secondary to pancreaticopleural fistula can be caused by ascending infection of enteric organisms from infected pancreatic pseudocysts. This unique route of infection should be noted for appropriate empirical antibiotic therapy.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2050-0904Test

الوصول الحر: https://doaj.org/article/ed24e056dccd40d192273a2c96befebbTest

المؤلفون: Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, Shunsuke Aburaya, Tomoko Yamamoto Funazo, Koh Furugaki, Yasushi Yoshimura, Masatoshi Yamazoe, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Hironori Yoshida, Yuichi Sakamori, Hiroaki Wake, Mitsuyoshi Ueda, Young Hak Kim, Toyohiro Hirai

المصدر: Nature Communications, Vol 11, Iss 1, Pp 1-16 (2020)

مصطلحات موضوعية: Science

الوصف: Relapse is a limitation for the efficacy of the anaplastic lymphoma kinase (ALK)-inhibitor alectinib in ALK-rearranged lung cancer. Here, the authors show that YAP1 activation upon alectinib treatment leads to therapy resistance and that inhibiting both YAP1 and ALK leads to longer tumor remission in mice.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2041-1723Test

الوصول الحر: https://doaj.org/article/3f80ddddea7640be87705e31f5e46a2aTest

المؤلفون: Hidetoshi Yoshioka, Masahito Emura, Naohide Takada, Natsuko Nomura, Shuta Igarashi, Takafumi Niwamoto, Takashi Nomizo, Takaya Nakamura, Yoshimi Nishikawa, Yusuke Kobayashi, 中村 敬哉, 五十嵐 修太, 吉岡 秀敏, 小林 祐介, 庭本 崇史, 江村 正仁, 西川 圭美, 野村 奈都子, 野溝 岳, 髙田 直秀

المصدر: 気管支学 / The Journal of the Japan Society for Respiratory Endoscopy. 2019, 41(3):278

المؤلفون: Haruka YAMAMOTO, Hideo KITA, Hiroko FUKATA, Takashi NOMIZO, Tsunetaka MURAYAMA, Yasukiyo NAKAMURA, 中村 保清, 北 英夫, 山本 晴香, 村山 恒峻, 深田 寛子, 野溝 岳

المصدر: 感染症学雑誌 / Kansenshogaku Zasshi. :22039

المؤلفون: TATSUYA OGIMOTO, HIROAKI OZASA, HIRONORI YOSHIDA, TAKASHI NOMIZO, TOMOKO FUNAZO, HIROSHI YOSHIDA, KENTARO HASHIMOTO, KAZUTAKA HOSOYA, MASATOSHI YAMAZOE, HITOMI AJIMIZU, TAKAHIRO TSUJI, YUICHI SAKAMORI, KIYOMITSU KUNINAGA, SATOSHI MORITA, TOYOHIRO HIRAI

المصدر: Oncology Letters; Aug2023, Vol. 26 Issue 2, p1-7, 7p

مصطلحات موضوعية: NON-small-cell lung carcinoma, CD47 antigen, NIVOLUMAB, SINGLE nucleotide polymorphisms, IMMUNE checkpoint inhibitors

الشركة/الكيان: KYOTO Daigaku

مستخلص: Immune checkpoint inhibitors (ICIs), such as nivolumab, play an essential role in non-small-cell lung cancer (NSCLC) treatment. Programmed death ligand-1 has been used as a predictive biomarker for the efficacy of ICI treatment in patients with NSCLC; however, its predictive value is considered insufficient. Therefore, there is an urgent need for better predictive biomarkers. The present study focused on the CD47 molecule, which is associated with macrophages and tumor immunity. The study aimed to investigate the association between CD47 single nucleotide polymorphism (SNP) and the therapeutic effect of nivolumab in patients with NSCLC. The CD47 SNP genotypes and clinical outcomes were retrospectively analyzed in 164 patients with NSCLC treated with nivolumab at Kyoto University Hospital (Kyoto, Japan). Patients with the G/G genotype of the CD47 SNP rs3804639 had significantly longer progression-free survival than those with the G/T or T/T genotypes [2.6 months vs. 2.1 months, hazard ratio (HR), 0.70; P=0.026]. Moreover, the G/G genotype of the CD47 SNP rs3804639 was associated with a significantly longer median overall survival than the G/T or T/T genotypes of the CD47 SNP rs3804639 (24.8 months vs. 12.0 months, HR, 0.64; P=0.021). In conclusion, CD47 polymorphism may be a novel predictive biomarker of nivolumab efficacy in patients with advanced NSCLC. [ABSTRACT FROM AUTHOR]

: Copyright of Oncology Letters is the property of Spandidos Publications UK Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Young Hak Kim, Toyohiro Hirai, Mitsuyoshi Ueda, Yuichi Sakamori, Hiroki Nagai, Yoshitaka Yagi, Hironori Yoshida, Koichi Hasegawa, Kiyoshi Uemasu, Takashi Nomizo, Yuto Yasuda, Ryoko Okutani, Hitomi Ajimizu, Yasushi Yoshimura, Koh Furugaki, Tomoko Funazo, Shunsuke Aburaya, Wataru Aoki, Hiroaki Ozasa, Takahiro Tsuji

الوصف: Fig. S1. Supplementary data for Fig. 1 Fig. S2. Supplementary drug sensitivity data to ALK inhibitors in KTOR1 and KTOR1-RE. Fig. S3. Supplementary results of the phosphoproteome analysis Fig. S4. Saracatinib sensitized KTOR1-RE cells to crizotinib Fig. S5. Combined knockdown of MET and SRC inhibited proliferation and induces apoptosis Fig. S6. Supplementary data for Fig. 6 Table S1. Primer sequences for direct sequence of ALK exons Table S2. Primer sequences for detection and sequence of EML4-ALK rearrangement Table S3. Primer sequences for qRT-PCR

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5f8b92c4e090d208d1fd9cf32555131Test
https://doi.org/10.1158/1541-7786.22515762Test